New Jersey cancer biosimilar developer Oncobiologics is aggressively pursuing cash: It raised $43 million earlier this year, and is looking for $50 million more, according to a regulatory filing.
Oncobiologics has a number of monoclonal antibody therapeutics in development, and is in the midst of clinical trials to get its Avastin biosimilar approved. It’s readying itself for Phase 3 trials for its Avastin-like biologic. The patents on Avastin are set to expire in 2019 – and there are a number of contenders in the race to develop a contender for bevacizumab.
Oncobiologics has another mAb in the clinic – a biosimilar for Humira. This should enter Phase 3 trials next year. Notably, AbbVie is slated to lose some patent protections of this immunosuppressant by the close of 2016.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Oncobiologics has six more biosimilars in preclinical study, the company says.
